Biotech company Alvotech S.A. (NASDAQ:ALVO) announced on Wednesday that it has initiated a confirmatory patient study for AVT16, a biosimilar candidate to Entyvio (vedolizumab).
The study aims to demonstrate comparative efficacy, safety and immunogenicity of AVT16 and Entyvio in patients with moderate to severe active ulcerative colitis.
Entyvio is indicated for the treatment of ulcerative colitis and Crohn's disease. With global sales of approximately USD5.4bn in the past 12 months, Entyvio is a significant market opportunity for biosimilars.
The AVT16-GL-C01 multicentre study will compare AVT16 to Entyvio in a double-blind parallel design. Participants will be followed to assess disease activity using a standardised score.
Alvotech's biosimilars portfolio targets various therapeutic areas, including autoimmune diseases, eye disorders, bone disease, respiratory disease and cancer. With two approved biosimilars and three additional candidates in development, Alvotech is expanding its presence in the biosimilars market.
Genprex partners with University of Michigan to explore Reqorsa for lung cancer treatment
United Therapeutics reaches milestone with 500th lung transplant via ex vivo lung perfusion service
Foresee Pharmaceuticals completes linvemastat (FP-020) phase clinical study in Australia
HUTCHMED's TAGRISSO plus ORPATHYS shows promise in lung cancer treatment
GSK reports positive Phase III results for depemokimab in chronic rhinosinusitis with nasal polyps
GE HealthCare expands AI-enabled enterprise imaging with Blackford integration
PureTech Health highlights progress in IPF research and LYT-100 at CHEST 2024
MediLink enters clinical trial collaboration and supply agreement with Amgen
Innovent Biologics partners with Jiangsu Aosaikang Pharmaceutical for lung cancer treatment
Genprex research collaborators to present positive data on Reqorsa Gene Therapy at SITC 2024
hVIVO reports positive results from RSV antiviral human challenge trial